PE20221518A1 - Analogos de incretina y sus usos - Google Patents
Analogos de incretina y sus usosInfo
- Publication number
- PE20221518A1 PE20221518A1 PE2022001115A PE2022001115A PE20221518A1 PE 20221518 A1 PE20221518 A1 PE 20221518A1 PE 2022001115 A PE2022001115 A PE 2022001115A PE 2022001115 A PE2022001115 A PE 2022001115A PE 20221518 A1 PE20221518 A1 PE 20221518A1
- Authority
- PE
- Peru
- Prior art keywords
- glucagon
- refers
- incretin analogs
- gip
- dyslipidemia
- Prior art date
Links
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 title abstract 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract 2
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 2
- 108060003199 Glucagon Proteins 0.000 abstract 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 2
- 229960004666 glucagon Drugs 0.000 abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Details Of Garments (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
SE REFIERE A ANALOGOS DE INCRETINA CUYAS SECUENCIAS DE AMINOACIDOS COMPRENDEN LAS SEC ID NO: 6 A 11, LOS CUALES TIENEN ACTIVIDAD EN CADA UNO DE LOS RECEPTORES DEL POLIPEPTIDO INSULINOTROPICO DEPENDIENTE DE GLUCOSA (GIP), EL PEPTIDO SIMILAR A GLUCAGON-1 (GLP-1) Y EL GLUCAGON (GCG). TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE LOS COMPRENDE, SIENDO UTILES EN EL TRATAMIENTO DE LA DIABETES MELLITUS TIPO 2, LA DISLIPIDEMIA, EL SINDROME METABOLICO, LA ENFERMEDAD DEL HIGADO GRASO NO ALCOHOLICO.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949661P | 2019-12-18 | 2019-12-18 | |
| PCT/US2020/064512 WO2021126695A1 (en) | 2019-12-18 | 2020-12-11 | Incretin analogs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221518A1 true PE20221518A1 (es) | 2022-10-04 |
Family
ID=74181298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001115A PE20221518A1 (es) | 2019-12-18 | 2020-12-11 | Analogos de incretina y sus usos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12410227B2 (es) |
| EP (1) | EP4077365A1 (es) |
| JP (1) | JP7450724B2 (es) |
| KR (1) | KR102824306B1 (es) |
| CN (1) | CN114787183B (es) |
| AR (1) | AR120714A1 (es) |
| AU (1) | AU2020408139B2 (es) |
| BR (1) | BR112022009396A2 (es) |
| CL (1) | CL2022001623A1 (es) |
| CO (1) | CO2022008264A2 (es) |
| CR (1) | CR20220279A (es) |
| DO (1) | DOP2022000122A (es) |
| EC (1) | ECSP22048612A (es) |
| IL (1) | IL293754A (es) |
| JO (1) | JOP20220153A1 (es) |
| MX (1) | MX2022007666A (es) |
| NZ (1) | NZ788683A (es) |
| PE (1) | PE20221518A1 (es) |
| PH (1) | PH12022551491A1 (es) |
| TW (1) | TWI795698B (es) |
| WO (1) | WO2021126695A1 (es) |
| ZA (1) | ZA202205443B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| CN115484972B (zh) | 2020-04-24 | 2025-07-01 | 勃林格殷格翰国际有限公司 | 作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物 |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| KR102873595B1 (ko) | 2021-09-15 | 2025-10-22 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 장애의 치료를 위한 조성물 및 방법 |
| JP7804766B2 (ja) * | 2021-11-19 | 2026-01-22 | チアンスー ディユアン ファーマシューティカル カンパニー リミテッド | ステープルペプチド及びその使用 |
| AU2024215381A1 (en) | 2023-01-31 | 2025-09-18 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
| CN118684758A (zh) * | 2023-03-23 | 2024-09-24 | 上海民为生物技术有限公司 | 肠促胰岛素类似物及其应用 |
| CN121002051A (zh) * | 2023-04-11 | 2025-11-21 | 上海多米瑞生物技术有限公司 | 肠促胰素类似物及其制备方法和应用 |
| CN120349393A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种三激动剂化合物 |
| WO2025259957A1 (en) * | 2024-06-14 | 2025-12-18 | Eli Lilly And Company | Compositions and methods for improving insulin sensitivity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013518115A (ja) * | 2010-01-27 | 2013-05-20 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物 |
| EA201390941A1 (ru) * | 2010-12-22 | 2013-12-30 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, проявляющие активность на рецепторе gip |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| US10131702B2 (en) | 2013-11-06 | 2018-11-20 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| EP3082847A1 (en) | 2013-12-20 | 2016-10-26 | Indiana University Research and Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| EA038544B1 (ru) | 2015-12-31 | 2021-09-13 | Ханми Фарм. Ко., Лтд. | Тройной агонист рецепторов глюкагона/glp-1/gip |
| SG10202109721PA (en) | 2016-03-10 | 2021-10-28 | Medimmune Ltd | Glucagon and glp-1 co-agonists for the treatment of obesity |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
-
2020
- 2020-12-10 TW TW109143561A patent/TWI795698B/zh active
- 2020-12-10 AR ARP200103435A patent/AR120714A1/es unknown
- 2020-12-11 JO JOP/2022/0153A patent/JOP20220153A1/ar unknown
- 2020-12-11 KR KR1020227020239A patent/KR102824306B1/ko active Active
- 2020-12-11 CR CR20220279A patent/CR20220279A/es unknown
- 2020-12-11 EP EP20839440.3A patent/EP4077365A1/en active Pending
- 2020-12-11 BR BR112022009396A patent/BR112022009396A2/pt unknown
- 2020-12-11 CN CN202080087802.4A patent/CN114787183B/zh active Active
- 2020-12-11 NZ NZ788683A patent/NZ788683A/en unknown
- 2020-12-11 IL IL293754A patent/IL293754A/en unknown
- 2020-12-11 PH PH1/2022/551491A patent/PH12022551491A1/en unknown
- 2020-12-11 US US17/785,758 patent/US12410227B2/en active Active
- 2020-12-11 WO PCT/US2020/064512 patent/WO2021126695A1/en not_active Ceased
- 2020-12-11 JP JP2022537359A patent/JP7450724B2/ja active Active
- 2020-12-11 PE PE2022001115A patent/PE20221518A1/es unknown
- 2020-12-11 MX MX2022007666A patent/MX2022007666A/es unknown
- 2020-12-11 AU AU2020408139A patent/AU2020408139B2/en active Active
-
2022
- 2022-05-17 ZA ZA2022/05443A patent/ZA202205443B/en unknown
- 2022-06-13 CO CONC2022/0008264A patent/CO2022008264A2/es unknown
- 2022-06-14 DO DO2022000122A patent/DOP2022000122A/es unknown
- 2022-06-15 CL CL2022001623A patent/CL2022001623A1/es unknown
- 2022-06-17 EC ECSENADI202248612A patent/ECSP22048612A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2022000122A (es) | 2022-07-31 |
| AU2020408139B2 (en) | 2024-03-28 |
| JP7450724B2 (ja) | 2024-03-15 |
| ECSP22048612A (es) | 2022-07-29 |
| AU2020408139A1 (en) | 2022-06-09 |
| US20230102339A1 (en) | 2023-03-30 |
| IL293754A (en) | 2022-08-01 |
| JP2023506952A (ja) | 2023-02-20 |
| CO2022008264A2 (es) | 2022-07-08 |
| WO2021126695A1 (en) | 2021-06-24 |
| TW202138385A (zh) | 2021-10-16 |
| AR120714A1 (es) | 2022-03-09 |
| NZ788683A (en) | 2026-01-30 |
| CL2022001623A1 (es) | 2023-01-20 |
| CA3162245A1 (en) | 2021-06-24 |
| ZA202205443B (en) | 2025-03-26 |
| CN114787183B (zh) | 2024-11-26 |
| PH12022551491A1 (en) | 2023-11-20 |
| BR112022009396A2 (pt) | 2022-08-09 |
| KR102824306B1 (ko) | 2025-06-25 |
| CN114787183A (zh) | 2022-07-22 |
| KR20220100676A (ko) | 2022-07-15 |
| EP4077365A1 (en) | 2022-10-26 |
| CR20220279A (es) | 2022-07-03 |
| TWI795698B (zh) | 2023-03-11 |
| MX2022007666A (es) | 2022-07-19 |
| JOP20220153A1 (ar) | 2023-01-30 |
| US12410227B2 (en) | 2025-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221518A1 (es) | Analogos de incretina y sus usos | |
| PE20211637A1 (es) | Compuestos coagonistas de gip/glp1 | |
| PE20200926A1 (es) | Peptidos analogos de incretina | |
| PE20170954A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| MX2023000403A (es) | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip). | |
| CL2020002574A1 (es) | Análogos novedosos de glp-1 | |
| AR079939A1 (es) | Composicion farmaceutica para tratar un sindrome metabolico | |
| CO2019005924A2 (es) | Agonistas duales acilados de glp-1/glp-2 | |
| MX2023000303A (es) | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. | |
| CO6280539A2 (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad | |
| AR121093A1 (es) | Compuestos coagonistas de gip / glp1 | |
| CO2025001430A2 (es) | Agonista dual de glp-1/gip, método de preparación y uso del mismo | |
| ECSP23071867A (es) | Composiciones que contienen análogos de incretina y usos de estas | |
| BR112015003916A2 (pt) | peptídeo selecionado a partir do grupo consistindo no peptídeo glp-1, no peptídeo gip e seus análogos resistentes a dipeptidil-peptidase iv (dpp-iv); e composição farmacêutica | |
| MX2022006743A (es) | Formulaciones liquidas estables de peptido 1 similar al glucagon o analogos del mismo. | |
| AR102406A1 (es) | Coagonistas de los receptores de glucagón y de glp-1 | |
| EA202092017A1 (ru) | Новые аналоги glp-1 |